PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions
Keywords: لیزوفسفاتیدیل کولین; PCSK9; Lipidomics; Lipoproteins; Atherosclerosis; Sphingolipids; Drug therapy; CAD; coronary artery disease; CE; cholesteryl ester; Cer; ceramide; DAG; diacylglycerol; Gb3; globotriasoylceramide; Glc/GalCer; glucosyl/galactosylceramide; GOF; gain-of-funct